Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
ARHGAP1 CDC42GAP, RHOGAP1
Sequence Length (AA) Molecular Weight (Da)
439 50436
Protein Name
Rho GTPase-activating protein 1
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MDPLSELQDD LTLDDTSEAL NQLKLASIDE KNWPSDEMPD FPKSDDSKSS
60 70 80 90 100
SPELVTHLKW DDPYYDIARH QIVEVAGDDK YGRKIIVFSA CRMPPSHQLD
110 120 130 140 150
HSKLLGYLKH TLDQYVESDY TLLYLHHGLT SDNKPSLSWL RDAYREFDRK
160 170 180 190 200
YKKNIKALYI VHPTMFIKTL LILFKPLISF KFGQKIFYVN YLSELSEHVK
210 220 230 240 250
LEQLGIPRQV LKYDDFLKST QKSPATAPKP MPPRPPLPNQ QFGVSLQHLQ
260 270 280 290 300
EKNPEQEPIP IVLRETVAYL QAHALTTEGI FRRSANTQVV REVQQKYNMG
310 320 330 340 350
LPVDFDQYNE LHLPAVILKT FLRELPEPLL TFDLYPHVVG FLNIDESQRV
360 370 380 390 400
PATLQVLQTL PEENYQVLRF LTAFLVQISA HSDQNKMTNT NLAVVFGPNL
410 420 430 439
LWAKDAAITL KAINPINTFT KFLLDHQGEL FPSPDPSGL

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for non-CPTAC-6080 Collapse assay details

Data source: Panorama

Official Gene Symbol
ARHGAP1
Peptide Sequence
AINPINTFTK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
412
Peptide End
421
CPTAC ID
non-CPTAC-6080
Peptide Molecular Mass
1,117.6132
Species
Homo sapiens (Human)
Assay Type
Direct MRM-MS
Matrix
Bovine Serum Albumin
Submitting Laboratory
McGill University
Submitting Lab PI
Christoph H. Borchers, Gerald Batist

Publication

View Details (opens in a new window)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Agilent 6495B QQQ-MS
Internal Standard
Standard Isotope labeled internal standard peptides with 13Cx, 15Ny (R+10 or K+8)
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Infinity 1290
Column Packing
commercial (Agilent ZORBAX Eclipse Plus C18)
Column Dimensions
4.6 mm × 150 mm, (5 µm)
Flow Rate
0.4 mL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b3 (1+) 8.5 4.5 4 8.2 4.2 3.9 11.8 6.2 5.6 16 16 17
y7 (1+) 4.8 4 6.1 6.6 3.8 6 8.2 5.5 8.6 16 16 17
y8 (1+) 8.2 3 5 9.2 4.9 4.9 12.3 5.7 7 16 16 17
y7 (2+) 6.8 4.6 9.2 8.3 4.6 6.8 10.7 6.5 11.4 16 16 17
y8 (2+) 5.6 5.9 6 5.4 6 8.4 7.8 8.4 10.3 16 16 17
sum 3 2.4 2.2 2.9 2.2 3.3 4.2 3.3 4 16 16 17


Stability

Data source: Panorama

Fragment ion / Transition control_intra_CV actual_temp_intra_CV frozen_intra_CV FTx1_intra_CV FTx2_intra_CV
b3 (1+) 8.2 9 3.5 13.2 9
y7 (1+) 9.1 4.3 5.9 8.8 7
y8 (1+) 7.6 3.6 7.8 9.6 3
y7 (2+) 9.2 9.8 3.9 4.7 4.5
y8 (2+) 12.1 8.3 5.7 11.9 3.8
sum 3.3 1.6 1.9 1.6 1.9
Fragment ion / Transition all_intra_CV all_inter_CV
b3 (1+) 8.7 6
y7 (1+) 6.6 5.8
y8 (1+) 5.9 7.1
y7 (2+) 7 5.4
y8 (2+) 8.4 7.9
sum 2 2.1

Endogenous

Data source: Panorama

Fragment ion / Transition intra_CV inter_CV total_CV
b3 (1+) 2.4 23.4 23.5
y7 (1+) 20.4 22.1 30.1
y8 (1+) 3.6 28.1 28.3
y7 (2+) 5 40.7 41
y8 (2+) 17.2 13.8 22.1
sum 9.8 20.2 22.5

Additional Resources and Comments